ILiAD Biotechnologies
PrivateLast Round
Series B
Feb 10, 2026
Est. Valuation
$176M
Total Funding Raised
$207M
Momentum Score
75 /100
Company Overview
ILiAD Biotechnologies is a biotechnology company that develops a medical vaccine aimed at preventing and treating diseases caused by Bordetella pertussis by inducing the immune system to produce protective antibodies against infections like whooping cough.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2G
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ILiAD Biotechnologies Comps
Public and private peers based on sector, stage, and business model.
ILiAD Biotechnologies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Feb 10, 2026 | ||||
| Series D | Sep 6, 2022 | ||||
| Grant | Apr 26, 2022 | ||||
| Convertible Debt | Mar 12, 2021 | ||||
| Series C | Dec 19, 2018 |
Key People
Founding team and executive leadership
ILiAD Biotechnologies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series B |
| RA Capital Management | Series B |
| National Institute of Allergy and Infectious Diseases | Grant |
| Knott Partners, LP | Series D |
| Network-1 Technologies | Convertible Debt, Series C |
| SDS Capital Partners | Series C |
| Seedlings Life Science Ventures | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 20, 2026
Monthly visitors increased 87% MoM.
ILiAD Biotechnologies Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about ILiAD Biotechnologies's valuation, stock price, and market status.
